Panitumumab: all 196 studies that test it

Page 2 of 2. Open to participants first (24), then studies with results posted, then the rest; newest registration first within each.

• Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO TrialCompletedNCT05468892Phase 2
• Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast CancerWithdrawnNCT05177796Phase 2
• CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without PanitumumabActive, not recruitingNCT05121038Phase 1/2
• Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal CancerCompletedNCT04425239Phase 2
• Lymph Node Ratio and Kras Mutation in R Colon CancerCompletedNCT04342676Phase 3
• Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS MutationTerminatedNCT04034173Phase 2
• Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFRStatus unknownNCT03940131Phase 2
• Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic ColorectalStatus unknownNCT03751176Phase 2
• Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal CancerActive, not recruitingNCT03635021Phase 3
• FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS MutationCompletedNCT03584711Phase 2
• Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal CancerTerminatedNCT03311750Phase 2
• Rechallenge With Panitumumab Driven by RAS Dynamic of ResistanceCompletedNCT03227926Phase 2
• Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy NetworkCompletedNCT03164655Phase 2
• FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance StatusCompletedNCT03142516Phase 2
• Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before SurgeryCompletedNCT03000374Phase 2
• Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer PatientsCompletedNCT02980510Phase 2
• Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast CancerActive, not recruitingNCT02876107Phase 2
• I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras MutationsCompletedNCT02818725Phase 3
• Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous CancerCompletedNCT02643056Phase 2
• Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)Status unknownNCT02476045Phase 2
• Panitumumab IRDye800 Optical Imaging StudyCompletedNCT02415881Phase 1
• A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal CancerCompletedNCT02399943Phase 2
• Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal CancerStatus unknownNCT02301962Phase 4
• Regorafenib + Panitumumab for Colorectal CancersTerminatedNCT02199223Phase 1
• Treatment Strategies in Colorectal Cancer Patients with Initially Unresectable Liver-only MetastasesCompletedNCT02162563Phase 3
• Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal CancerCompletedNCT02008383Phase 1
• Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal CancerCompletedNCT01991873Phase 2
• Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal CanalTerminatedNCT01843452Phase 2
• A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal CancerStatus unknownNCT01801904Phase 2
• Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive TechniquesCompletedNCT01704703Phase 2
• Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell CancerTerminatedNCT01627379Phase 3
• P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.CompletedNCT01591421Phase 1/2
• Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver MetastasesTerminatedNCT01508000Phase 2
• Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal CancerCompletedNCT01443377Phase 2
• MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal AdenocarcinomaCompletedNCT01443065Phase 2
• Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian CancerStatus unknownNCT01388621Phase 2
• Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type PatientsStatus unknownNCT01384994Phase 2
• PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial CancerTerminatedNCT01374789Phase 2
• FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal CancerCompletedNCT01358812Phase 2
• Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric AdenocarcinomaTerminatedNCT01351038Phase 2
• FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)CompletedNCT01328171Phase 2
• PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)CompletedNCT01320254Phase 2
• Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent PanitumumabWithdrawnNCT01312493Phase 2
• Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal CancerCompletedNCT01288339Phase 2
• Vectibix for the Treatment of Anal CancerCompletedNCT01285778Phase 2
• Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck CancerCompletedNCT01264328Phase 2
• A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver MetastasesCompletedNCT01260415Phase 2
• Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)Status unknownNCT01257360Phase 2
• ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal JunctionCompletedNCT01234324Phase 2
• Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer PatientsCompletedNCT01215539Phase 2
• Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS MutationsCompletedNCT01206049Phase 2
• Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic CancerCompletedNCT01175733Phase 1/2
• Study of Panitumumab in the Treatment of Carcinoid SyndromeWithdrawnNCT01172717Phase 2
• Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical CancerStatus unknownNCT01158248Phase 2
• A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line ChemotherapyStatus unknownNCT01144195Phase 2
• Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of RecurrenceWithdrawnNCT01142414Phase 3
• Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal CancerCompletedNCT01139138Phase 1/2
• Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC)Status unknownNCT01129154Phase 2
• Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal CancerCompletedNCT01126112Phase 2
• Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal CancerStatus unknownNCT01110785Phase 2
• Neoadjuvant Treatment of Colon CancerCompletedNCT01108107Phase 2
• Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung CancerSuspendedNCT01088620Phase 2
• Chemoradiation and Panitumumab for Esophageal CancerCompletedNCT01077999Phase 2
• A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007CompletedNCT01061788Phase 1
• First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung CancerTerminatedNCT01038037Phase 2
• Trial of Radiotherapy and Panitumumab in Salivary Gland MalignanciesWithdrawnNCT00984217Phase 2
• Preoperative Panitumumab and Radiotherapy in Rectal CancerTerminatedNCT00973193Phase 2
• Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal CancerStatus unknownNCT00967655Phase 2
• Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)CompletedNCT00958386Phase 2
• Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal CancerTerminatedNCT00950820Phase 2
• Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.CompletedNCT00933517Phase 2
• Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only MetastasesCompletedNCT00885885Phase 2
• KRAS Wild-type Metastatic Colorectal Cancer TrialCompletedNCT00879385Phase 1
• Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-typeCompletedNCT00861120Phase 2
• Biomarker - Panitumumab Response With KRAS Wild Type MCCCompletedNCT00853931Not applicable
• Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal CancerCompletedNCT00814619Phase 2
• Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS MutationsCompletedNCT00792363Phase 2
• Combined Biological Treatment and Chemotherapy for Patients With Inoperable CholangiocarcinomaCompletedNCT00779454Phase 2
• Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by SurgeryStatus unknownNCT00647530Phase 2/3
• Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to TreatmentCompletedNCT00610948Phase 1
• BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)CompletedNCT00586443Phase 1
• Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRCCompletedNCT00475293Phase 2
• Study for Patients Who Have Benefited and Tolerated Prior Panitumumab TreatmentCompletedNCT00425204Phase 2
• Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2CompletedNCT00425035Phase 2
• Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to FluorouracilCompletedNCT00389870Phase 3
• Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal CancerCompletedNCT00327119Phase 2
• Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal CancerCompletedNCT00113776Phase 2
• Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinomaCompletedNCT00111774Phase 2
• ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT00101920Phase 2
• Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal CancerCompletedNCT00101894Phase 1
• Two Dose Schedules of Panitumumab in Subjects With Advanced Solid TumorsCompletedNCT00091806Phase 1
• ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the BodyCompletedNCT00061126Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Prostate CancerCompletedNCT00054574Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal CancerCompletedNCT00039273Phase 2
• ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT00034346Phase 2
• Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction CancerCompletedNCT00004879Phase 1

← Panitumumab overview